BRPI1016117A2 - derivados de isoxazol-isoxazol e isoxasol-isotiazol. - Google Patents

derivados de isoxazol-isoxazol e isoxasol-isotiazol.

Info

Publication number
BRPI1016117A2
BRPI1016117A2 BRPI1016117A BRPI1016117A BRPI1016117A2 BR PI1016117 A2 BRPI1016117 A2 BR PI1016117A2 BR PI1016117 A BRPI1016117 A BR PI1016117A BR PI1016117 A BRPI1016117 A BR PI1016117A BR PI1016117 A2 BRPI1016117 A2 BR PI1016117A2
Authority
BR
Brazil
Prior art keywords
isoxazole
isoxasol
isothiazole derivatives
isothiazole
derivatives
Prior art date
Application number
BRPI1016117A
Other languages
English (en)
Inventor
Andrew Thomas
Maria-Clemencia Hernandez
Matthew C Lucas
Roland Jakob-Roetne
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1016117A2 publication Critical patent/BRPI1016117A2/pt
Publication of BRPI1016117A8 publication Critical patent/BRPI1016117A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
BRPI1016117A 2009-02-19 2010-02-16 derivados de isoxazol-isoxazol e isoxazol-isotiazol. BRPI1016117A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09153162 2009-02-19
PCT/EP2010/051890 WO2010094669A1 (en) 2009-02-19 2010-02-16 Isoxazole-isoxazole and isoxazole-isothiazole derivatives

Publications (2)

Publication Number Publication Date
BRPI1016117A2 true BRPI1016117A2 (pt) 2016-04-12
BRPI1016117A8 BRPI1016117A8 (pt) 2018-01-02

Family

ID=42111584

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1016117A BRPI1016117A8 (pt) 2009-02-19 2010-02-16 derivados de isoxazol-isoxazol e isoxazol-isotiazol.

Country Status (15)

Country Link
US (1) US8173652B2 (pt)
EP (1) EP2398782B1 (pt)
JP (1) JP5478640B2 (pt)
KR (1) KR101361465B1 (pt)
CN (1) CN102317270B (pt)
AR (1) AR075517A1 (pt)
AU (1) AU2010215515A1 (pt)
BR (1) BRPI1016117A8 (pt)
CA (1) CA2749649C (pt)
ES (1) ES2431617T3 (pt)
IL (1) IL213974A0 (pt)
MX (1) MX2011007774A (pt)
SG (1) SG173666A1 (pt)
TW (1) TW201033201A (pt)
WO (1) WO2010094669A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
PT2797416T (pt) 2011-12-28 2017-10-23 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
MY180206A (en) 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) * 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
DK3102208T3 (da) 2014-02-07 2021-03-08 Global Blood Therapeutics Inc Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
PT3880654T (pt) 2018-11-19 2022-04-08 Global Blood Therapeutics Inc Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina
JP2024517223A (ja) 2021-05-05 2024-04-19 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド 認知障害の治療に有用なヘテロアリール化合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525205A1 (de) 1984-09-11 1986-03-20 Hoechst Ag, 6230 Frankfurt Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols
GB9808663D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic agents
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IT1314191B1 (it) 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
US6511987B1 (en) 1999-11-12 2003-01-28 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
EP1411942A4 (en) 2001-07-05 2005-01-26 Synaptic Pharma Corp SUBSTITUTED ANILINE PIPERIDINES AS SELECTIVE MCH ANTAGONISTS
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
JP2005518357A (ja) 2001-11-20 2005-06-23 イーライ・リリー・アンド・カンパニー ベータ3アドレナリンアゴニスト
GB0128160D0 (en) * 2001-11-23 2002-01-16 Merck Sharp & Dohme Novel compounds
EP1562915A1 (en) 2002-11-22 2005-08-17 SmithKline Beecham Corporation Farnesoid x receptor agonists
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
EP1756086B1 (en) 2004-06-01 2008-06-04 F.Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
PL1802566T3 (pl) 2004-10-01 2009-05-29 Hoffmann La Roche Podstawione heksafluoroizopropanolem pochodne eteru
WO2006044617A1 (en) 2004-10-15 2006-04-27 The Scripps Research Institute Oxadiazole ketone inhibitors of fatty acid amide hydrolase
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2007009274A2 (de) 2005-07-20 2007-01-25 Prospective Concepts Ag Pneumatisch verstellbare seitenwangen für fahrzeugsitze
JP2009508905A (ja) * 2005-09-19 2009-03-05 エフ.ホフマン−ラ ロシュ アーゲー GABAAα5逆アゴニストとしてのイソオキサゾロ誘導体
JP2009511533A (ja) * 2005-10-11 2009-03-19 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾール誘導体
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
EP1962838B1 (en) 2005-12-19 2011-09-28 GlaxoSmithKline LLC Farnesoid x receptor agonists
ES2397401T3 (es) * 2005-12-23 2013-03-06 F. Hoffmann-La Roche Ag Derivados de aril-isoxazol-4-il-oxadiazol
AU2006331437B2 (en) * 2005-12-27 2012-07-05 F. Hoffmann-La Roche Ag Aryl-Isoxazol-4-yl-Imidazole derivatives
CN101374834B (zh) 2006-02-03 2011-12-14 伊莱利利公司 用于调节fxr的化合物和方法
JP2007230909A (ja) 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
WO2007137954A1 (en) * 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
KR101384829B1 (ko) * 2009-05-05 2014-04-15 에프. 호프만-라 로슈 아게 이속사졸-피라졸 유도체

Also Published As

Publication number Publication date
EP2398782B1 (en) 2013-09-18
CN102317270A (zh) 2012-01-11
US8173652B2 (en) 2012-05-08
KR101361465B1 (ko) 2014-02-10
AU2010215515A1 (en) 2011-08-11
WO2010094669A1 (en) 2010-08-26
IL213974A0 (en) 2011-08-31
BRPI1016117A8 (pt) 2018-01-02
MX2011007774A (es) 2011-08-12
AR075517A1 (es) 2011-04-06
TW201033201A (en) 2010-09-16
CA2749649C (en) 2017-04-04
US20100210651A1 (en) 2010-08-19
EP2398782A1 (en) 2011-12-28
JP2012518025A (ja) 2012-08-09
CA2749649A1 (en) 2010-08-26
SG173666A1 (en) 2011-09-29
KR20110120322A (ko) 2011-11-03
CN102317270B (zh) 2014-10-08
ES2431617T3 (es) 2013-11-27
JP5478640B2 (ja) 2014-04-23

Similar Documents

Publication Publication Date Title
BRPI1016117A2 (pt) derivados de isoxazol-isoxazol e isoxasol-isotiazol.
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
BRPI1012883A2 (pt) dispositivo intercorporal.
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
BRPI1013844A2 (pt) derivados de piridina-isoxazol
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
DK2397480T3 (da) Diazepindionderivat
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
BR112012002877A2 (pt) dilatador e conjunto.
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BRPI1007811A2 (pt) nacela de turborreator, e, turborreator
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
DK2387580T3 (da) Deoxyactagardinderivater
BRPI1016192A2 (pt) derivados de soxazol.
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
DK2442870T3 (da) Pyrazinooxazepin-derivater.
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
IT1396487B1 (it) Convogliatore.
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
BRPI1011416A2 (pt) derivados de antraquinova novos
FR2947857B1 (fr) Agencement de deshuileur
BRPI0922652A2 (pt) Derivados de quinazolinamida
FR2941674B1 (fr) Nacelle de turboreacteur.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2553 DE 2019-12-10